Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Resignation

On January 20, 2021, Kaleido Biosciences, Inc. (the "Company") and Katharine Knobil, M.D. reached a mutual agreement that Dr. Knobil will resign from her position as Chief Medical Officer and Head of Research and Development of the Company, effective as of January 29, 2021 (the "Effective Date"). Dr. Knobil is leaving the Company in order to pursue other opportunities and her decision to resign was not the result of any disagreement with the Company on any matters relating to the Company's operations, policies or practices.

In connection with her departure, the Company and Dr. Knobil entered into a separation agreement and general release dated as of January 25, 2021 (the "Separation Agreement"). Pursuant to the terms of the Separation Agreement, for a twelve-month period following the Effective Date, Dr. Knobil will receive salary continuation payments. Dr. Knobil will also provide consulting services to the Company from the Effective Date through April 15, 2021 (the "Departure Date"). She will be entitled to receive a one-time payment of up to 100% of her target bonus for 2020 based on the achievement by the Company of its 2020 corporate objectives, as determined by the Company's Board of Directors. In addition, under the Separation Agreement: (i) 15,843 of the restricted stock units granted to Dr. Dr. Knobil on February 28, 2020 shall accelerate and vest effective on the Departure Date; (ii) 12,500 of the restricted stock units granted to Dr. Knobil on November 15, 2019 shall accelerate and vest effective on the Departure Date; (iii) fifty percent (50%) of the options granted to Dr. Knobil on April 15, 2020 shall accelerate and vest effective on the Departure Date; and (iv) Dr. Knobil's other outstanding equity awards shall continue to vest through the Departure Date. The Separation Agreement also contains confidentiality, non-disparagement and non-solicitation covenants and a release of claims by Dr. Knobil.

The foregoing summary is not complete and is qualified in its entirety by the Separation Agreement, a copy of which is attached hereto as Exhibit 10.1 and is incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.



(d) Exhibits:



Exhibit No.   Description

                Separation Agreement, dated January 25, 2021, by and between Kaleido
10.1          Biosciences, Inc. and Katharine Knobil.
              Cover Page Interactive Data File (embedded within the Inline XBRL
104           document).

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses